Issue 4, 2017

Design and synthesis of cenocladamide analogues and their evaluation against breast cancer cell lines

Abstract

This work describes the total synthesis of the alkaloid cenocladamide and a concise library of nine structural analogues aiming at their evaluation against the breast cancer cell line MDA-MB-231. The most promising compound (3; IC50 = 6.6 μM) was also evaluated in a panel of seven breast cancer cell lines and two non-tumorigenic cell lines. We further conducted an initial investigation on the mechanism of action of analogue 3, which lacks the endocyclic double bond when compared to cenocladamide. The present study presents the discovery of a cenocladamide analogue with interesting cytotoxic activity, which could be useful for further optimization towards new chemotherapeutic agents for breast cancer treatment.

Graphical abstract: Design and synthesis of cenocladamide analogues and their evaluation against breast cancer cell lines

Supplementary files

Article information

Article type
Research Article
Submitted
14 Oct 2016
Accepted
21 Nov 2016
First published
25 Nov 2016

Med. Chem. Commun., 2017,8, 755-766

Design and synthesis of cenocladamide analogues and their evaluation against breast cancer cell lines

C. C. F. Santos, L. S. Paradela, L. F. T. Novaes, S. M. G. Dias and J. C. Pastre, Med. Chem. Commun., 2017, 8, 755 DOI: 10.1039/C6MD00577B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements